BIAF Reports 92% Sensitivity, 87% Specificity for CyPath® Lung in Lung Cancer Detection, Supports Deferral of Invasive Biopsy
bioAffinity Technologies, Inc. Common Stock · SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH · Now $1.75
Post-detection moves
1h
—
1d
—
3d
—
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS